Liver Transplant Rejection – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Liver Transplant Rejection – Pipeline Review, H2 2016’, provides an overview of the Liver Transplant Rejection pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Liver Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Liver Transplant Rejection and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Liver Transplant Rejection

The report reviews pipeline therapeutics for Liver Transplant Rejection by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Liver Transplant Rejection therapeutics and enlists all their major and minor projects

The report assesses Liver Transplant Rejection therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Liver Transplant Rejection

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Liver Transplant Rejection

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Liver Transplant Rejection pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Astellas Pharma Inc.

Biogen Inc

Conatus Pharmaceuticals Inc.

Digna Biotech, S.L.

Dompe Farmaceutici S.p.A.

Novartis AG

RedHill Biopharma Ltd.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Liver Transplant Rejection Overview 7

Therapeutics Development 8

Pipeline Products for Liver Transplant Rejection - Overview 8

Pipeline Products for Liver Transplant Rejection - Comparative Analysis 9

Liver Transplant Rejection - Therapeutics under Development by Companies 10

Liver Transplant Rejection - Therapeutics under Investigation by Universities/Institutes 11

Liver Transplant Rejection - Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Liver Transplant Rejection - Products under Development by Companies 15

Liver Transplant Rejection - Products under Investigation by Universities/Institutes 16

Liver Transplant Rejection - Companies Involved in Therapeutics Development 17

Astellas Pharma Inc. 17

Biogen Inc 18

Conatus Pharmaceuticals Inc. 19

Digna Biotech, S.L. 20

Dompe Farmaceutici S.p.A. 21

Novartis AG 22

RedHill Biopharma Ltd. 23

Liver Transplant Rejection - Therapeutics Assessment 24

Assessment by Monotherapy Products 24

Assessment by Target 25

Assessment by Mechanism of Action 27

Assessment by Route of Administration 29

Assessment by Molecule Type 31

Drug Profiles 33

ABC-294640 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Cardiotrophin-1 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Cellular Immunotherapy for Liver Transplantation - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Cellular Immunotherapy for Liver Transplantation - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

emricasan - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

everolimus - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

FX-06 - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

reparixin - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

rituximab - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

tacrolimus ER - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

TR-002 - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

Liver Transplant Rejection - Dormant Projects 71

Liver Transplant Rejection - Discontinued Products 72

Liver Transplant Rejection - Product Development Milestones 73

Featured News & Press Releases 73

Nov 16, 2015: Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting 73

May 12, 2014: Conatus Pharmaceuticals Initiates Phase 2b Trial Targeting Fibrosis in Liver Transplant Recipients 73

Nov 02, 2013: Conatus Pharmaceuticals Presents Data Demonstrating Emricasan's Safety Profile at the AASLD Liver Meeting 74

Dec 04, 2012: Astellas Pharma Announces Acceptance Of US New Drug Application For Tacrolimus Extended Release Capsules 75

Oct 20, 2011: European Medicines Agency Agrees To Precautionary Recall Of Advagraf

0.5mg Capsule Batches 75

Jul 01, 2011: Astellas Introduces Advagraf In India 76

Mar 16, 2011: Digna Biotech And Biotecnol Receive Spanish Approval For Phase I Clinical Studies Of Cardiotrophin I 76

Feb 18, 2011: Astellas Introduces Advagraf in China-once daily administration, leading the new trend in immunosuppressive therapy after organ transplant 76

Oct 02, 2007: New Once-Daily Advagraf Launched Across Europe. 77

Jun 18, 2007: Advagraf Now Available in Germany and the UK as a Once-Daily Immunosuppressant in Organ Transplantation 78

Apr 30, 2007: Advagraf Now Approved Across Europe as a Once-Daily Immunosuppressant in Organ Transplantation. 79

Appendix 80

Methodology 80

Coverage 80

Secondary Research 80

Primary Research 80

Expert Panel Validation 80

Contact Us 80

Disclaimer 81

List of Tables

List of Tables

Number of Products under Development for Liver Transplant Rejection, H2 2016 8

Number of Products under Development for Liver Transplant Rejection – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Clinical Stage Development, H2 2016 13

Comparative Analysis by Early Stage Development, H2 2016 14

Products under Development by Companies, H2 2016 15

Products under Investigation by Universities/Institutes, H2 2016 16

Liver Transplant Rejection – Pipeline by Astellas Pharma Inc., H2 2016 17

Liver Transplant Rejection – Pipeline by Biogen Inc, H2 2016 18

Liver Transplant Rejection – Pipeline by Conatus Pharmaceuticals Inc., H2 2016 19

Liver Transplant Rejection – Pipeline by Digna Biotech, S.L., H2 2016 20

Liver Transplant Rejection – Pipeline by Dompe Farmaceutici S.p.A., H2 2016 21

Liver Transplant Rejection – Pipeline by Novartis AG, H2 2016 22

Liver Transplant Rejection – Pipeline by RedHill Biopharma Ltd., H2 2016 23

Assessment by Monotherapy Products, H2 2016 24

Number of Products by Stage and Target, H2 2016 26

Number of Products by Stage and Mechanism of Action, H2 2016 28

Number of Products by Stage and Route of Administration, H2 2016 30

Number of Products by Stage and Molecule Type, H2 2016 32

Liver Transplant Rejection – Dormant Projects, H2 2016 71

Liver Transplant Rejection – Discontinued Products, H2 2016 72

List of Figures

List of Figures

Number of Products under Development for Liver Transplant Rejection, H2 2016 8

Number of Products under Development for Liver Transplant Rejection – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Clinical Stage Development, H2 2016 13

Comparative Analysis by Early Stage Products, H2 2016 14

Assessment by Monotherapy Products, H2 2016 24

Number of Products by Top 10 Targets, H2 2016 25

Number of Products by Stage and Top 10 Targets, H2 2016 25

Number of Products by Top 10 Mechanism of Actions, H2 2016 27

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 27

Number of Products by Routes of Administration, H2 2016 29

Number of Products by Stage and Routes of Administration, H2 2016 29

Number of Products by Molecule Types, H2 2016 31

Number of Products by Stage and Molecule Types, H2 2016 31

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports